- Home
- SISI vs CNSP Comparison
SISI vs CNSP Comparison
Compare SISI & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- CNSP
- Stock Information
- Founded
- SISI 1997
- CNSP 2017
- Country
- SISI China
- CNSP United States
- Employees
- SISI N/A
- CNSP N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- CNSP Health Care
- Exchange
- SISI Nasdaq
- CNSP Nasdaq
- Market Cap
- SISI 5.9M
- CNSP 5.4M
- IPO Year
- SISI 2016
- CNSP 2019
- Fundamental
- Price
- SISI $2.77
- CNSP $0.12
- Analyst Decision
- SISI
- CNSP Strong Buy
- Analyst Count
- SISI 0
- CNSP 1
- Target Price
- SISI N/A
- CNSP $0.50
- AVG Volume (30 Days)
- SISI 162.8K
- CNSP 10.6M
- Earning Date
- SISI 11-14-2024
- CNSP 11-15-2024
- Dividend Yield
- SISI N/A
- CNSP N/A
- EPS Growth
- SISI N/A
- CNSP N/A
- EPS
- SISI N/A
- CNSP N/A
- Revenue
- SISI $10,330,284.00
- CNSP N/A
- Revenue This Year
- SISI N/A
- CNSP N/A
- Revenue Next Year
- SISI N/A
- CNSP N/A
- P/E Ratio
- SISI N/A
- CNSP N/A
- Revenue Growth
- SISI 370.34
- CNSP N/A
- 52 Week Low
- SISI $2.24
- CNSP $0.10
- 52 Week High
- SISI $117.65
- CNSP $121.00
- Technical
- Relative Strength Index (RSI)
- SISI 39.09
- CNSP 47.75
- Support Level
- SISI $2.24
- CNSP $0.11
- Resistance Level
- SISI $3.10
- CNSP $0.15
- Average True Range (ATR)
- SISI 0.47
- CNSP 0.02
- MACD
- SISI 0.13
- CNSP 0.00
- Stochastic Oscillator
- SISI 27.00
- CNSP 50.95
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.